Pancreatic neuroendocrine tumour metastatic – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 10:36:44 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Pancreatic neuroendocrine tumour metastatic – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study of 64Cu-DOTATATE and 18F-FDG PET/CT imaging to predict disease progression in patients with neuroendocrine neoplasms https://clinicaltrials.eu/trial/study-on-pet-ct-imaging-with-64cu-dotatate-and-18f-fdg-for-patients-with-neuroendocrine-tumors/ Wed, 29 Apr 2026 15:00:27 +0000 https://clinicaltrials.eu/trial/study-on-pet-ct-imaging-with-64cu-dotatate-and-18f-fdg-for-patients-with-neuroendocrine-tumors/ This study focuses on patients with Neuroendocrine Neoplasms (tumors that develop from cells of the hormone system). The research uses two different imaging substances: 64Cu-DOTATATE and 18F-FDG, which are special solutions given through an injection into a vein. These substances help create detailed images of tumors using a special type of scanning called PET/CT (a combination of two imaging techniques that produces detailed pictures of the body’s internal structures).

The purpose of this study is to develop new ways to predict how long patients with neuroendocrine neoplasms might remain stable without their disease getting worse. This will be done by analyzing measurements from combined scans using both imaging substances. During the study, participants will receive both types of imaging solutions and undergo PET/CT scanning.

Both imaging substances are given as single injections into a vein. 64Cu-DOTATATE attaches to specific receptors found on neuroendocrine tumors, while 18F-FDG helps show how active the tumor cells are. The combination of these two different types of scans provides doctors with more complete information about the tumor’s characteristics and behavior.

]]> Study of Combined Imaging with Hyperpolarized [1-13C]Pyruvate and Fludeoxyglucose (18F) for Cancer Detection in Patients with Breast Cancer, Neuroendocrine Tumors, Lymphomas, or Sarcomas https://clinicaltrials.eu/trial/study-on-imaging-techniques-using-pyruvic-acid-and-fludeoxyglucose-18f-for-patients-with-breast-cancer-neuroendocrine-tumors-lymphomas-and-sarcomas/ Wed, 29 Apr 2026 15:00:05 +0000 https://clinicaltrials.eu/trial/study-on-imaging-techniques-using-pyruvic-acid-and-fludeoxyglucose-18f-for-patients-with-breast-cancer-neuroendocrine-tumors-lymphomas-and-sarcomas/ This study focuses on testing a new imaging method in patients with various types of cancer, including breast cancer, neuroendocrine neoplasms, lymphomas, and sarcomas. The research combines two different imaging techniques: Magnetic Resonance Spectroscopy using a substance called hyperpolarized [1-13C]pyruvate and PET scanning using Fluor-18-FDG (a radioactive form of glucose).

The purpose of this study is to determine whether it is possible to perform both imaging methods at the same time to better understand how tumors use energy. During the study, participants will receive two different injectable substances: hyperpolarized [1-13C]pyruvate and Fluor-18-FDG. Both substances will be given through an intravenous injection, and then special images will be taken using a combined PET/MR scanner.

This research will help doctors better understand how tumors process different nutrients and may lead to improved ways of detecting and monitoring cancer. The imaging procedure will be performed once for each participant, and the total dose of each substance has been carefully calculated to ensure safety.

]]>